CKD-504

Chong Kun Dang Pharmaceutical · Phase 1 active Small molecule

At a glance

Generic name	CKD-504
Also known as	HDAC inhibitor
Sponsor	Chong Kun Dang Pharmaceutical
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CKD-504 CI brief — competitive landscape report
CKD-504 updates RSS · CI watch RSS
Chong Kun Dang Pharmaceutical portfolio CI